Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results entities : Lexicon pharmaceuticals, inc. save search
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 6.91%
H: 21.55%
C: 21.12%
business update pharmaceuticals results
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -10.4%
H: 10.71%
C: 1.79%
business update pharmaceuticals financial results
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
Published: 2023-11-03 (Crawled : 13:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -1.43%
H: 8.7%
C: 7.25%
conference pharmaceuticals financial results
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -0.94%
H: 14.05%
C: 11.43%
lx9211 association meeting diabetes results study
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
Published: 2023-08-21 (Crawled : 13:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.0%
H: 7.23%
C: 4.82%
heart cardiology results study
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -6.25%
H: 3.89%
C: 3.89%
business update pharmaceuticals financial results
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
Published: 2023-07-28 (Crawled : 20:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
| Email alert
Add to watchlist
conference pharmaceuticals financial results
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: -2.07%
lx9211 sessions diabetes results study
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Published: 2023-05-02 (Crawled : 20:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 4.62%
H: 11.64%
C: 10.04%
business update pharmaceuticals financial results
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
Published: 2023-04-28 (Crawled : 21:00) - biospace.com/
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.85%
H: 3.57%
C: 0.42%
conference pharmaceuticals financial results
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
Published: 2023-04-21 (Crawled : 13:20) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 2.04%
H: 2.4%
C: -0.4%
lx9211 meeting trial results
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Published: 2023-03-02 (Crawled : 21:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.92%
H: 29.55%
C: 21.82%
pharmaceuticals financial update results
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
Published: 2023-02-28 (Crawled : 22:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.44%
H: 1.77%
C: -2.65%
pharmaceuticals conference financial results
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
Published: 2022-12-21 (Crawled : 00:00) - biospace.com/
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.52%
H: 3.63%
C: -1.55%
lx9211 topline results study phase 2
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Published: 2022-11-14 (Crawled : 22:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 3.43%
H: 2.07%
C: -3.73%
lx9211 treatment trial therapeutics results benefits diabetic
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Published: 2022-11-09 (Crawled : 23:00) - biospace.com/
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: -0.97%
H: 0.49%
C: -3.92%
pharmaceuticals financial update results
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
Published: 2022-11-08 (Crawled : 14:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.94%
H: 0.47%
C: -4.19%
lx9211 pharmaceuticals trial therapeutics presentation results
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
Published: 2022-11-06 (Crawled : 00:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.96%
H: 4.05%
C: 1.43%
risk heart
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
Published: 2022-11-04 (Crawled : 13:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.47%
H: 0.47%
C: -3.26%
pharmaceuticals conference financial results
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-02 (Crawled : 09:00) - globenewswire.com
LXRX | $1.66 2.47% 910K
|
Health Technology
|
| O: 0.38%
H: 6.51%
C: 3.07%
update results
Gainers vs Losers
| 83% | 17% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0504 35.12% 300M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.